COLL vs. XBI
Compare and contrast key facts about Collegium Pharmaceutical, Inc. (COLL) and SPDR S&P Biotech ETF (XBI).
XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: COLL or XBI.
Correlation
The correlation between COLL and XBI is 0.40, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
COLL vs. XBI - Performance Comparison
Key characteristics
COLL:
-0.56
XBI:
-0.40
COLL:
-0.58
XBI:
-0.39
COLL:
0.93
XBI:
0.95
COLL:
-0.59
XBI:
-0.18
COLL:
-1.17
XBI:
-1.02
COLL:
20.64%
XBI:
10.51%
COLL:
43.11%
XBI:
26.79%
COLL:
-73.59%
XBI:
-63.89%
COLL:
-35.71%
XBI:
-56.52%
Returns By Period
In the year-to-date period, COLL achieves a -6.07% return, which is significantly higher than XBI's -16.15% return.
COLL
-6.07%
-10.45%
-26.19%
-22.76%
5.59%
N/A
XBI
-16.15%
-13.32%
-23.06%
-8.70%
-4.19%
-0.16%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
COLL vs. XBI — Risk-Adjusted Performance Rank
COLL
XBI
COLL vs. XBI - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Collegium Pharmaceutical, Inc. (COLL) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
COLL vs. XBI - Dividend Comparison
COLL has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.18%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
COLL Collegium Pharmaceutical, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.18% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% |
Drawdowns
COLL vs. XBI - Drawdown Comparison
The maximum COLL drawdown since its inception was -73.59%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for COLL and XBI. For additional features, visit the drawdowns tool.
Volatility
COLL vs. XBI - Volatility Comparison
Collegium Pharmaceutical, Inc. (COLL) and SPDR S&P Biotech ETF (XBI) have volatilities of 14.37% and 14.76%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.